Nonetheless, the struggling Tanox managed to complete Phase II clinical trials (which seek primarily to verify safe and effect dosages) for TMB-355-then known as TNX-355-and obtain FDA permission to proceed with further trials.
在美國苦撐的 Tanox，最後還是完成了當時仍以「TNX-355」命名的愛滋新藥第二期臨床試驗，確認出藥物的療效與安全性，並經美國 FDA 審核認可。